Department of Ophthalmology, Chungnam National University, College of Medicine, Daejeon, South Korea.
Retina. 2011 Jul-Aug;31(7):1287-93. doi: 10.1097/IAE.0b013e3182003ccd.
To evaluate the efficacy of intravitreal ranibizumab (Lucentis) with verteporfin photodynamic therapy for patients with polypoidal choroidal vasculopathy.
Retrospective interventional case series. Seventeen eyes of 17 patients with symptomatic polypoidal choroidal vasculopathy who received 3 monthly intravitreal ranibizumab injections with photodynamic therapy were retrospectively reviewed. The follow-up period lasted for more than 6 months after therapy. Best-corrected visual acuity, foveal thickness determined by optical coherence tomography, and abnormal vasculature in indocyanine green angiography were evaluated.
The mean follow-up period was 13.8 months. The mean logarithm of the minimum angle of resolution best-corrected visual acuity was 0.43 ± 0.36 at baseline, 0.14 ± 0.24 at 6 months (P = 0.01), and 0.11 ± 0.23 at 12 months after treatment (P = 0.02). The mean foveal height was 351 ± 111 μm at baseline, 192 ± 44 μm at 6 months (P = 0.02), and 204 ± 31 μm at 12 months after treatment (P = 0.01). Patients received a mean of 3.2 ranibizumab treatments and 1.3 verteporfin photodynamic therapy treatments over the follow-up period. Re-treatment was performed in 5 of 17 eyes. The polypoidal lesions on indocyanine green angiography were regressed in six eyes, reduced in seven eyes, and unchanged in four eyes.
Intravitreal ranibizumab with photodynamic therapy may stabilize visual acuity and reduce exudative retinal detachment because of decreased vascular leaking. The combination treatment appeared to be useful for regressing polypoidal lesions on indocyanine green angiography and in reducing their recurrence.
评估玻璃体内雷珠单抗（Lucentis）联合维替泊芬光动力疗法治疗息肉状脉络膜血管病变患者的疗效。
回顾性干预性病例系列研究。回顾性分析了 17 例 17 只眼有症状的息肉状脉络膜血管病变患者，这些患者接受了 3 次每月一次的玻璃体内雷珠单抗注射联合光动力疗法治疗。治疗后随访期超过 6 个月。评估最佳矫正视力、光学相干断层扫描测量的中心凹厚度和吲哚青绿血管造影的异常血管。
平均随访期为 13.8 个月。治疗前平均最小分辨角对数视力为 0.43 ± 0.36，治疗后 6 个月为 0.14 ± 0.24（P = 0.01），治疗后 12 个月为 0.11 ± 0.23（P = 0.02）。治疗前中心凹高度平均为 351 ± 111 μm，治疗后 6 个月为 192 ± 44 μm（P = 0.02），治疗后 12 个月为 204 ± 31 μm（P = 0.01）。患者在随访期间平均接受 3.2 次雷珠单抗治疗和 1.3 次维替泊芬光动力疗法治疗。17 只眼中有 5 只需要再次治疗。6 只眼的息肉样病变在吲哚青绿血管造影上消退，7 只眼减少，4 只眼不变。
玻璃体内雷珠单抗联合光动力疗法可能通过减少血管渗漏稳定视力和减少渗出性视网膜脱离。联合治疗似乎对消退吲哚青绿血管造影上的息肉样病变和减少其复发有效。
